Company Profile

MGB Biopharma is developing a truly novel class of anti-infectives. Its lead candidate, MGB-BP-3, is an antibacterial which is active against a broad range of important multi-resistant Gram-positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile that is ready to enter the clinic, whilst an intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development. MGB Biopharma has close links with the University of Strathclyde, with exclusive worldwide licence rights to the University's MGB patents for all fields except anti-cancer. The Company intends to work with partners to fully capitalise on the multiple value creating opportunities offered by its broad and novel anti-infectives platform. The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is backed by Scottish investors including Archangel Investors, Barwell, TRI Cap and the Scottish Investment Bank, Scottish Enterprise.